Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival

Table 2

Univariate analysis of the patient cohort.

Variable	Response	No response	value
HRS type 1/2,	47/18	45/9	0.165
Ascites, grade 1/2/3	9/38/18	11/25/16	0.466
Treatment, median days (IRQ)	9 6–14	10.5 5–19	0.350
HE, grade 1/2/3	46/15/3	39/14/1	0.699
Serum protein, g/L	5.84 ± 1.27	5.30 ± 1.47	0.040
INR	1.60 ± 0.52	1.64 ± 0.44	0.698
Serum sodium (mmol/L)	133.60 ± 6.21	133.12 ± 5.73	0.714
Serum potassium (mmol/L)	4.34 ± 0.80	4.22 ± 0.71	0.381
Serum creatinine (mg/dL)	2.79 ± 1.24	3.07 ± 1.47	0.207
Urea (mg/dL)	55.30 ± 24.68	67.47 ± 51.59	0.189
Bilirubin (mg/dL)	8.12 ± 10.23	10.59 ± 12.29	0.901
Terlipressin dose (mg)	26.43 ± 30.86	32.11 ± 31.57	0.450
Albumin dose (g)	266.26 ± 236.31	298.14 ± 252.02	0.612

HE: hepatic encephalopathy; INR: international normalized ratio.